SCHEMBL12371499

SCHEMBL12371499

COC(=O)COC1C[C@H](C(=O)Nc2ccc3c(c2)C(C)CN(C)CC3)N(C(=O)Nc2ccc(Br)cc2)C1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 4/20 0.39
▸ KDM4E B2RXH2 1/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ CFD P00746 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ MET P08581 2/20 0.33
▸ ALK Q9UM73 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KLKB1 P03952 2/20 0.33
▸ ABCB1 P08183 1/20 0.33
▸ ABCG2 Q9UNQ0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12371500 0.93 F10 (0.39) F10KDM4EKMT2AMEN1CFD
SCHEMBL14434664 0.92 F10 (0.39) F10KMT2ACFDNPC1MET
SCHEMBL12371503 0.90 F10 (0.41) F10KDM4EKMT2AMEN1CFD
SCHEMBL14434670 0.85 F10 (0.39) F10KMT2AALDH1A1NPC1MET
SCHEMBL12371502 0.84 F10 (0.41) F10KDM4EKMT2AMEN1CFD
SCHEMBL12371435 0.82 F10 (0.49) F10KMT2AMEN1CFDMET
SCHEMBL12371434 0.82 F10 (0.49) F10KMT2AMEN1CFDMET
SCHEMBL14434665 0.82 F10 (0.41) F10KMT2ACFDNPC1MET
SCHEMBL8220410 0.82 F10 (0.42) F10KDM4EKMT2AMEN1CFD
SCHEMBL13104352 0.82 F10 (0.42) F10KDM4EKMT2AMEN1CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003639-B2 Substituted prolinamides, the preparation thereof and the use thereof as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-23 — — US disclosed
US-8003639-B2 Substituted prolinamides, the preparation thereof and the use thereof as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-23 — — US disclosed
US-20090048231-A1 SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 — — US disclosed
US-20090048231-A1 SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048231-A1 SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS PREP, P4HA1, PPID F10 1628/4885KDM4E 2663/4885KMT2A 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback